| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/12/2012 | WO2012006551A2 Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
| 01/12/2012 | WO2012006550A2 Methods and compositions for treatment of lipogenic virus related conditions |
| 01/12/2012 | WO2012006500A2 Monoclonal antibodies against hepatitis c virus core protein |
| 01/12/2012 | WO2012006419A2 Pro-neurogenic compounds |
| 01/12/2012 | WO2012006329A2 Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| 01/12/2012 | WO2012006202A1 Rho kinase inhibitors |
| 01/12/2012 | WO2012006117A2 Reduction of microglia-mediated neurotoxicity by kca3.1 inhibition |
| 01/12/2012 | WO2012006004A1 Prokineticin 1 receptor antagonists for the treatment of pain |
| 01/12/2012 | WO2012006003A1 Prokineticin 1 receptor antagonists for the treatment of pain |
| 01/12/2012 | WO2012005885A2 Nutraceutical product containing anatabine and yerba maté |
| 01/12/2012 | WO2012005605A1 A combination composition comprising ibuprofen and paracetamol |
| 01/12/2012 | WO2012005379A1 Transformant obtained by introducing gm1 gene and crmp2 gene |
| 01/12/2012 | WO2012005328A1 Antibody capable of binding to lysophosphatidylglucoside, and composition containing the antibody |
| 01/12/2012 | WO2012005229A1 N-hydroxyformamide derivative and pharmaceutical containing same |
| 01/12/2012 | WO2012004917A1 Neurite outgrowth agent |
| 01/12/2012 | WO2012004900A1 Thienopyrimidine compounds |
| 01/12/2012 | WO2012004714A2 Chemical compounds |
| 01/12/2012 | WO2012004706A2 Chemical compounds |
| 01/12/2012 | WO2012004698A1 Piperidinyl pyrimidine amides as kv7 potassium channel openers |
| 01/12/2012 | WO2012004610A1 Delivery of hydrophilic peptides |
| 01/12/2012 | WO2012004585A1 Ingestible formulation comprising glycomacropeptide and at least one of tryptophan, tyrosine and phenylalanine and uses thereof |
| 01/12/2012 | WO2012004378A1 Spiro-cyclic amine derivatives as s1p modulators |
| 01/12/2012 | WO2012004375A1 Bisaryl (thio)morpholine derivatives as s1p modulators |
| 01/12/2012 | WO2012004373A1 Fused heterocyclic derivatives as s1p modulators |
| 01/12/2012 | WO2012004291A1 Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients. |
| 01/12/2012 | WO2012004207A1 (3 -methylpyrrolidin- 3 - yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists |
| 01/12/2012 | WO2012004206A1 Anellated pyridine compounds |
| 01/12/2012 | WO2012003968A1 Novel gastro- retentive dosage forms comprising a gaba analog and an opioid |
| 01/12/2012 | WO2012003912A1 Bipyridyl derivatives useful for the treatment of kinase - induced diseases |
| 01/12/2012 | WO2012003802A1 Use of 5α-androstane (alkyl)-3β,5,6β-triol in preparing neuroprotective drugs |
| 01/12/2012 | WO2012003784A1 Pyrazine derivatives,process for manufacture and use thereof |
| 01/12/2012 | WO2012003554A2 Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates |
| 01/12/2012 | WO2011146821A3 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence |
| 01/12/2012 | WO2011123842A9 Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain |
| 01/12/2012 | WO2011117322A3 Use of caffeine and aspirin in synergistic amounts for improving performance |
| 01/12/2012 | WO2011116356A3 Positive allosteric modulators of group ii mglurs |
| 01/12/2012 | WO2011115416A3 Sedum sarmentosum fraction for breaking down alcohol and providing hangover relief |
| 01/12/2012 | WO2011107867A3 Compound and composition and their use in the treatment of diseases related to copper retention |
| 01/12/2012 | WO2011105825A3 Resveratrol effective in treating and preventing prion diseases |
| 01/12/2012 | WO2011087765A3 Methods of producing stabilized solid pharmaceutical compositions containing morphinans |
| 01/12/2012 | WO2011047173A3 Pharmaceutical compositions for oral administration |
| 01/12/2012 | US20120010296 Treating various disorders with catechol-o-methyl-transferase inhibitors |
| 01/12/2012 | US20120010293 Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| 01/12/2012 | US20120010283 Modulation of anxiety through blockade of anandamide hydrolysis |
| 01/12/2012 | US20120010282 Tautomycetin and Tautomycetin Analog Biosynthesis |
| 01/12/2012 | US20120010265 Crystalline form of a 3-phenoxymethylpyrrolidine compound |
| 01/12/2012 | US20120010264 Novel medicament for treating cognitive impairment |
| 01/12/2012 | US20120010263 Acetylene derivatives having mglur 5 antagonistic activity |
| 01/12/2012 | US20120010260 Method for treating nervous system disorders and conditions |
| 01/12/2012 | US20120010257 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/12/2012 | US20120010256 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 01/12/2012 | US20120010242 Low dose pipamperone in treating mood disorders |
| 01/12/2012 | US20120010228 D2 antagonists, methods of synthesis and methods of use |
| 01/12/2012 | US20120010225 Pharmaceutical composition |
| 01/12/2012 | US20120010224 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines |
| 01/12/2012 | US20120010223 Isothiazolo-pyrimidinedione derivatives as trpai modulators |
| 01/12/2012 | US20120010219 Salvinorin derivatives and uses thereof |
| 01/12/2012 | US20120010216 Pharmaceutical compositions containing vanoxerine |
| 01/12/2012 | US20120010214 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES |
| 01/12/2012 | US20120010213 Oral controlled release dosage forms for water soluble drugs |
| 01/12/2012 | US20120010212 Methyl-pyrrolidine ether derivatives |
| 01/12/2012 | US20120010210 L-Methylfolate Treatment for Psychiatric or Neurologic Disorders |
| 01/12/2012 | US20120010209 IMIDAZO[1,2-A]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS |
| 01/12/2012 | US20120010208 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
| 01/12/2012 | US20120010206 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases |
| 01/12/2012 | US20120010203 Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| 01/12/2012 | US20120010201 Novel anellated pyridine compounds |
| 01/12/2012 | US20120010199 Novel pyrrolinone derivative and pharmaceutical composition comprising the same |
| 01/12/2012 | US20120010197 Protein kinase inhibitors |
| 01/12/2012 | US20120010196 Methods of treating neurodegenerative disorders and diseases |
| 01/12/2012 | US20120010193 Cgrp receptor antagonists |
| 01/12/2012 | US20120010192 Fused Heterocyclic Compounds as Ion Channel Modulators |
| 01/12/2012 | US20120010191 Pyridone and aza-pyridone compounds and methods of use |
| 01/12/2012 | US20120010188 Imidazopyridine Compounds |
| 01/12/2012 | US20120010185 New pyridone derivates with mch antagonistic activity and medicaments comprising these compounds |
| 01/12/2012 | US20120010182 Chemical Compounds |
| 01/12/2012 | US20120010181 Compounds for the treatment of inflammatory disorders |
| 01/12/2012 | US20120010178 Methods and compounds for treatment of neurodegenerative disorders |
| 01/12/2012 | US20120010174 Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin |
| 01/12/2012 | US20120010156 Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| 01/12/2012 | US20120010148 Combination therapies using nap |
| 01/12/2012 | US20120010147 Nmdar biomarkers for diagnosis and treatment of traumatic brain injury and other disorders |
| 01/12/2012 | US20120010140 Self-assembling peptides for regeneration and repair of neural tissue |
| 01/12/2012 | US20120010136 Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders |
| 01/12/2012 | US20120010125 Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders |
| 01/12/2012 | US20120010124 Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell |
| 01/12/2012 | US20120009648 DNA polymerase lambda and uses thereof |
| 01/12/2012 | US20120009288 Use of acacia extracts and their compounds on inhibition of xanthine oxidase |
| 01/12/2012 | US20120009278 Composition To Retard the Onset of Symptoms of Alzheimer's Disease |
| 01/12/2012 | US20120009273 Kit of pharmaceutical formulations characterized by the presence of molecular oxygen |
| 01/12/2012 | US20120009271 Method of disease-induced and receptor-mediated stem cell neuroprotection |
| 01/12/2012 | US20120009268 Modified Virus Vectors and Methods of Making and Using the Same |
| 01/12/2012 | US20120009266 Composition comprising ocaperidone |
| 01/12/2012 | US20120009261 Novel gastro-retentive dosage forms |
| 01/12/2012 | US20120009249 Controlled release delivery system for nasal application of neurotransmitters |
| 01/12/2012 | US20120009245 Administration of Growth Factors for the Treatment of CNS Disorders |
| 01/12/2012 | US20120009226 Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| 01/12/2012 | US20120009196 Monoclonal antibodies against hepatitis c virus core protein |
| 01/12/2012 | US20120009195 Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| 01/12/2012 | US20120009192 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |